{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:00:08Z","timestamp":1792166408823,"version":"4.4.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.revmed.2020.08.019","type":"journal-article","created":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T08:34:59Z","timestamp":1604738099000},"page":"110-119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Maladie de Fabry\u00a0: quand y penser\u00a0?"],"prefix":"10.1016","volume":"42","author":[{"given":"M.","family":"Michaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Mauhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Belmatoug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Bedreddine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Garnotel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Catros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Lidove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Gaches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2020.08.019_bib0335","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.revmed.2020.08.019_bib0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjms.2020.07.011","article-title":"When and how to diagnose Fabry disease in clinical practice?","author":"Michaud","year":"2020","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.revmed.2020.08.019_bib0345","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson\u2013Fabry disease: clinical manifestations and impact of disease in a cohort of 60\u00a0obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"10.1016\/j.revmed.2020.08.019_bib0350","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson\u2013Fabry disease: clinical manifestations and impact of disease in a cohort of 98\u00a0hemizygous males","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"10.1016\/j.revmed.2020.08.019_bib0355","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course","volume":"81","author":"Branton","year":"2002","journal-title":"Medicine"},{"key":"10.1016\/j.revmed.2020.08.019_bib0360","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1093\/ndt\/gfq306","article-title":"Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy","volume":"26","author":"Sanchez-Ni\u00f1o","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.revmed.2020.08.019_bib0365","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-020-10044-w","article-title":"Oxidative stress biomarkers in Fabry disease: is there a room for them?","author":"Simoncini","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.revmed.2020.08.019_bib0370","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/cge.12449","article-title":"Diagnostic dilemmas in Fabry disease: a case series study on GLA mutations of unknown clinical significance","volume":"88","author":"Smid","year":"2015","journal-title":"Clin Genet"},{"key":"10.1016\/j.revmed.2020.08.019_bib0375","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.revmed.2020.08.019_bib0380","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/humu.21074","article-title":"Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936 919G>A (IVS4 919G>A)","volume":"30","author":"Hwu","year":"2009","journal-title":"Hum Mutat"},{"key":"10.1016\/j.revmed.2020.08.019_bib0385","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.revmed.2020.08.019_bib0390","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/jhg.2011.31","article-title":"Fabry-database.org: database of the clinical phenotypes, genotypes and mutant \u03b1-galactosidase A structures in Fabry disease","volume":"56","author":"Saito","year":"2011","journal-title":"J Hum Genet"},{"key":"10.1016\/j.revmed.2020.08.019_bib0395","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1651-2227.2005.tb02119.x","article-title":"Genotype and phenotype in Fabry disease: analysis of the Fabry Outcome Survey","volume":"94","author":"Schaefer","year":"2005","journal-title":"Acta Paediatr Suppl"},{"key":"10.1016\/j.revmed.2020.08.019_bib0400","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1096-7192(03)00136-7","article-title":"Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma","volume":"80","author":"Froissart","year":"2003","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.revmed.2020.08.019_bib0405","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","article-title":"Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry","volume":"11","author":"Waldek","year":"2009","journal-title":"Genet Med"},{"key":"10.1016\/j.revmed.2020.08.019_bib0410","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.acvd.2019.01.002","article-title":"Fabry disease in cardiology practice: literature review and expert point of view","volume":"112","author":"Hag\u00e8ge","year":"2019","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.revmed.2020.08.019_bib0415","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jacc.2010.11.018","article-title":"Cardiovascular events in patients with Fabry disease","volume":"57","author":"Patel","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.revmed.2020.08.019_bib0420","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/heartjnl-2014-306782","article-title":"Clinical and genetic predictors of major cardiac events in patients with Anderson\u2013Fabry disease","volume":"101","author":"Patel","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.revmed.2020.08.019_bib0425","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.revmed.2019.01.001","article-title":"Les cardiomyopathies hypertrophiques","volume":"40","author":"Lairez","year":"2019","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2020.08.019_bib0430","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.beem.2014.10.003","article-title":"Fabry disease and the heart","volume":"29","author":"Seydelmann","year":"2015","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.revmed.2020.08.019_bib0435","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/ndt\/gfm848","article-title":"Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy","volume":"23","author":"Ortiz","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.revmed.2020.08.019_bib0440","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.2215\/CJN.04340510","article-title":"Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry registry","volume":"5","author":"Wanner","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.revmed.2020.08.019_bib0445","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1097\/01.ASN.0000124671.61963.1E","article-title":"Results of a nationwide screening for Anderson\u2013Fabry disease among dialysis patients","volume":"15","author":"Kotanko","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.revmed.2020.08.019_bib0450","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ymgme.2012.03.010","article-title":"Small fibre neuropathy in Fabry disease","volume":"106","author":"Biegstraaten","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.revmed.2020.08.019_bib0455","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00431-003-1299-3","article-title":"The early clinical phenotype of Fabry disease: a study on 35\u00a0European children and adolescents","volume":"162","author":"Ries","year":"2003","journal-title":"Eur J Pediat"},{"key":"10.1016\/j.revmed.2020.08.019_bib0460","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/STROKEAHA.114.006283","article-title":"Cerebrovascular involvement in Fabry disease","volume":"46","author":"Kolodny","year":"2015","journal-title":"Stroke"},{"key":"10.1016\/j.revmed.2020.08.019_bib0465","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.08.010","article-title":"Prevalence of Fabry disease in stroke patients \u2013 a systematic review and meta-analysis","volume":"23","author":"Shi","year":"2014","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.revmed.2020.08.019_bib0470","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00392-018-1285-4","article-title":"Value of the CHA2DS2-VASc score and Fabry-specific score for predicting new-onset or recurrent stroke\/TIA in Fabry disease patients without atrial fibrillation","volume":"107","author":"Liu","year":"2018","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.revmed.2020.08.019_bib0475","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1212\/WNL.0000000000002673","article-title":"Determinants of white matter hyperintensity burden in patients with Fabry disease","volume":"86","author":"Rost","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.revmed.2020.08.019_bib0480","doi-asserted-by":"crossref","first-page":"e01121","DOI":"10.1002\/brb3.1121","article-title":"Absence of infratentorial lesions in Fabry disease contributes to differential diagnosis with multiple sclerosis","volume":"8","author":"Ugga","year":"2018","journal-title":"Brain Behav"},{"key":"10.1016\/j.revmed.2020.08.019_bib0485","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s00415-008-0786-x","article-title":"The pulvinar sign: frequency and clinical correlations in Fabry disease","volume":"255","author":"Burlina","year":"2008","journal-title":"J Neurol"},{"key":"10.1016\/j.revmed.2020.08.019_bib0490","doi-asserted-by":"crossref","first-page":"e0137603","DOI":"10.1371\/journal.pone.0137603","article-title":"Eight-year follow-up of neuropsychiatric symptoms and brain structural changes in Fabry disease","volume":"10","author":"Lelieveld","year":"2015","journal-title":"Plos One"},{"key":"10.1016\/j.revmed.2020.08.019_bib0495","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s10545-007-0708-6","article-title":"Depression in adults with Fabry disease: a common and under-diagnosed problem","volume":"30","author":"Cole","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.revmed.2020.08.019_bib0500","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1651-2227.2003.tb00219.x","article-title":"Auditory and vestibular findings in Fabry disease: a study of hemizygous males and heterozygous females","volume":"92","author":"Conti","year":"2007","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.revmed.2020.08.019_bib0505","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.cgh.2007.08.012","article-title":"Gastrointestinal symptoms in 342\u00a0patients with Fabry disease: prevalence and response to enzyme replacement therapy","volume":"5","author":"Hoffmann","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.revmed.2020.08.019_bib0510","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1212\/WNL.32.5.498","article-title":"Fabry disease: impaired autonomic function","volume":"32","author":"Cable","year":"1982","journal-title":"Neurology"},{"key":"10.1016\/j.revmed.2020.08.019_bib0515","doi-asserted-by":"crossref","first-page":"e780","DOI":"10.1097\/MD.0000000000000780","article-title":"Prevalence of Raynaud phenomenon and nailfold capillaroscopic abnormalities in Fabry disease: a cross-sectional study","volume":"94","author":"Deshayes","year":"2015","journal-title":"Medicine"},{"key":"10.1016\/j.revmed.2020.08.019_bib0520","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2133.2007.08002.x","article-title":"Fabry disease and the skin: data from FOS, the Fabry outcome survey","volume":"157","author":"Orteu","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.revmed.2020.08.019_bib0525","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/bjophthalmol-2014-306433","article-title":"Cornea verticillata supports a diagnosis of Fabry disease in non-classical phenotypes: results from the Dutch cohort and a systematic review","volume":"100","author":"van der Tol","year":"2016","journal-title":"Br J Ophtalm"},{"key":"10.1016\/j.revmed.2020.08.019_bib0530","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/ICO.0b013e3182107c8e","article-title":"A significant drug\u2013drug interaction detected through corneal examination: resolution of cornea verticillata while using amiodarone","volume":"31","author":"Mehta","year":"2012","journal-title":"Cornea"},{"key":"10.1016\/j.revmed.2020.08.019_bib0535","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/bjophthalmol-2019-314249","article-title":"Cornea verticillata in Fabry disease: a comparative study between slit-lamp examination and in vivo corneal confocal microscopy","volume":"104","author":"Leonardi","year":"2019","journal-title":"Br J Ophtalm"},{"key":"10.1016\/j.revmed.2020.08.019_bib0540","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1399-0004.2005.00457.x","article-title":"Osteopenia and osteoporosis: previously unrecognised manifestations of Fabry disease","volume":"68","author":"Germain","year":"2005","journal-title":"Clin Genet"},{"key":"10.1016\/j.revmed.2020.08.019_bib0545","first-page":"26721","article-title":"Fabry disease, respiratory symptoms, and airway limitation \u2013 a systematic review","volume":"2","author":"Svensson","year":"2015","journal-title":"Eur Clin Resp"},{"key":"10.1016\/j.revmed.2020.08.019_bib0550","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13023-015-0296-8","article-title":"Quality of life in patients with Fabry disease: a systematic review of the literature","volume":"10","author":"Arends","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.revmed.2020.08.019_bib0555","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterisation of classical and non-classical Fabry disease: a multicentre study","volume":"28","author":"Arends","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.revmed.2020.08.019_bib0560","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/jmedgenet-2014-102872","article-title":"Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease","volume":"52","author":"Smid","year":"2015","journal-title":"J Med Genet"},{"key":"10.1016\/j.revmed.2020.08.019_bib0565","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","article-title":"Fabry disease: baseline medical characteristics of a cohort of 1765\u00a0males and females in the Fabry Registry","volume":"30","author":"Eng","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.revmed.2020.08.019_bib0570","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.revmed.2019.11.010","article-title":"Mucopolysaccharidoses\u00a0: quand y penser\u00a0?","volume":"41","author":"Michaud","year":"2020","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2020.08.019_bib0575","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ymgme.2010.03.020","article-title":"Plasma globotriaosylsphingosine as a biomarker of Fabry disease","volume":"100","author":"Togawa","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.revmed.2020.08.019_bib0580","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbadis.2010.05.003","article-title":"Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease","volume":"1802","author":"Rombach","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.revmed.2020.08.019_bib0585","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.3390\/ijms19123726","article-title":"Mutations in the GLA gene and LysoGb3: is it really Anderson\u2013Fabry disease?","volume":"19","author":"Duro","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.revmed.2020.08.019_bib0590","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.revmed.2020.08.019_bib0595","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cca.2019.10.031","article-title":"\u03b1-Galactosidase A\/lysoGb3\u00a0ratio as a potential marker for Fabry disease in females","volume":"501","author":"Baydakova","year":"2020","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.revmed.2020.08.019_bib0600","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10545-017-0127-2","article-title":"Globotriaosylsphingosine (Lyso-Gb) as a biomarker for cardiac variant (N215S) Fabry disease","volume":"41","author":"Alharbi","year":"2018","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.revmed.2020.08.019_bib0605","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.revmed.2020.08.019_bib0610","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/gim.2016.122","article-title":"The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat","volume":"19","author":"Benjamin","year":"2017","journal-title":"Genet Med"},{"key":"10.1016\/j.revmed.2020.08.019_bib0615","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.cca.2015.10.027","article-title":"Pitfalls in the detection of gross gene rearrangements using MLPA in Fabry disease","volume":"452","author":"Ferri","year":"2016","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.revmed.2020.08.019_bib0620","series-title":"Protocole national de diagnostic et de soins (PNDS) Maladie de Fabry","author":"Haute Autorit\u00e9 de Sant\u00e9","year":"2010"},{"key":"10.1016\/j.revmed.2020.08.019_bib0625","doi-asserted-by":"crossref","first-page":"A30","DOI":"10.1016\/j.revmed.2015.03.251","article-title":"\u00c9valuation des connaissances des patients atteints d\u2019une maladie de Fabry","volume":"36","author":"Michaud","year":"2015","journal-title":"Rev Med Interne Suppl"},{"key":"10.1016\/j.revmed.2020.08.019_bib0630","first-page":"100454","article-title":"The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of experts","volume":"19","author":"Germain","year":"2019","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.revmed.2020.08.019_bib0635","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ymgme.2018.09.007","article-title":"The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease \u2013 a systematic literature review by a European panel of experts","volume":"126","author":"Germain","year":"2019","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.revmed.2020.08.019_bib0640","article-title":"New drugs for the treatment of Anderson\u2013Fabry disease","author":"Feriozzi","year":"2020","journal-title":"J Nephrol"},{"key":"10.1016\/j.revmed.2020.08.019_bib0645","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.1960","article-title":"An expert consensus document on the management of cardiovascular manifestations of Fabry disease","author":"Linhart","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.revmed.2020.08.019_bib0650","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1016\/j.ymgme.2017.12.401","article-title":"Therapeutic goals in Fabry disease: European expert consensus recommendations based on current clinical evidence","volume":"123","author":"Wanner","year":"2018","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.revmed.2020.08.019_bib0655","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ymgme.2018.04.004","article-title":"Therapeutic goals in Fabry disease: recommendations of a European expert panel, based on current clinical evidence with enzyme replacement therapy","volume":"126","author":"Wanner","year":"2019","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.revmed.2020.08.019_bib0330","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s13023-019-1254-7","article-title":"Treatment needs and expectations for Fabry disease in France: development of a new Patient Needs Questionnaire","volume":"14","author":"No\u00ebl","year":"2019","journal-title":"Orphanet J Rare Dis"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866320303684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866320303684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:42:53Z","timestamp":1759336973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866320303684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0248866320303684"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2020.08.019","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maladie de Fabry\u00a0: quand y penser\u00a0?","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2020.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}